Medical News

RSS

Spectral commences pivotal Toraymyxin trial for severe sepsis

Spectral Diagnostics Inc., a Phase III company seeking FDA approval for its lead theranostics product for the treatment severe sepsis and septic shock, today announced initiation of its U.S. pivotal trial of Toraymyxin™, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream, for patients with severe sepsis.

20 Oct 2010

ASBP reviews current rules of prescription medication to treat obesity in Kansas

In response to the alarming increase in the overweight and obese population in Kansas, a representative of the American Society of Bariatric Physicians (ASBP) recently testified to the Kansas State Board of Healing Arts. ASBP is America's oldest and most experienced society devoted to the medical treatment of overweight and obesity and associated health conditions and risks.

20 Oct 2010

New research blames billions in medical costs on obesity

Joint research from Cornell University and Lehigh University finds that nearly 17% of U.S. medical costs can be blamed on obesity.

20 Oct 2010

European Commission grants orphan drug status to OBI-1 for hemophilia treatment

Inspiration Biopharmaceuticals, Inc. announced today that the European Commission has granted orphan drug status for OBI-1 for the treatment of hemophilia.

20 Oct 2010

Candidates continue to clash over health care law

Candidates around the nation are increasingly focusing on what they'll do with the new health law if they're elected as clashes over the overhaul's usefulness and future continue to occur on the campaign trail.

20 Oct 2010

En Ze Jia Shi Pharmaceuticals receives patent for controlled-release oral gliclazide

Lotus Pharmaceuticals, Inc.a fast-growing, profitable developer, manufacturer and seller of medicine and drugs in the People's Republic of China announced today that its wholly owned subsidiary, En Ze Jia Shi Pharmaceuticals, has been issued a patent by the State Intellectual Property Office of the People's Republic of China for controlled-release oral gliclazide. The patent covers the composition and preparation methods for the drug through 2030.

20 Oct 2010

Gilead Sciences third quarter total revenues increase 8% to $1.94 billion

Gilead Sciences, Inc. announced today its results of operations for the quarter ended September 30, 2010. Total revenues for the third quarter of 2010 were $1.94 billion, up 8 percent compared to total revenues of $1.80 billion for the third quarter of 2009. Net income for the third quarter of 2010 was $704.9 million, or $0.83 per diluted share, compared to net income for the third quarter of 2009 of $673.0 million, or $0.72 per diluted share.

20 Oct 2010

As state commissioners meet on medical loss ratio, insurers warn of impact

Insurers are warning that a provision in the health law that requires them to spend 80 or 85 percent of premiums they collect on actual medical costs and not administrative expenses could put them out of business.

20 Oct 2010

Long term exposure to air pollution increases risk of severe COPD

Long term exposure to low-level air pollution may increase the risk of severe chronic obstructive pulmonary disease (COPD), according to researcher s in Denmark. While acute exposure of several days to high level air pollution was known to be a risk factor for exacerbation in pre-existing COPD, until now there had been no studies linking long-term air pollution exposure to the development or progression of the disease.

20 Oct 2010

454 Life Sciences enters co-promotional agreement with Fluidigm

454 Life Sciences, a Roche Company, and Fluidigm Corporation announced today that they have entered a worldwide co-promotional agreement for the companies' complementary amplicon sample preparation and high-throughput sequencing platforms.

20 Oct 2010

State Roundup: Md.'s heath info exchange; LA to cut retiree health benefits; N.Y.'s mental health building boom

The Washington Post: "A Maryland health information exchange that will allow hospitals, physicians, labs and radiology centers to share patient information within the state went live last week. Three hospitals, three radiology centers, Quest Diagnostics and the Laboratory Corp. of America are already participating in the exchange."

20 Oct 2010

CIED implantation with AIGISRx Antibacterial Envelope reduces overall infection rate

Patients undergoing CIED (Cardiac Implantable Electronic Device) implantation with TYRX, Inc.'s FDA-cleared AIGISRx Antibacterial Envelope enjoyed a 99.5% rate of successful implantation with an overall infection rate of 0.48% in the first 1.9 months following the procedure, as reported in newly published results of TYRX's COMMAND Clinical Study.

20 Oct 2010

Alexza reacquires U.S. and Canadian rights for Staccato Loxapine from BLS

Alexza Pharmaceuticals, Inc. announced today that it has reacquired the U.S. and Canadian rights for AZ-004 (Staccato® loxapine) from Biovail Laboratories International SRL, a wholly-owned subsidiary of Valeant Pharmaceuticals International, Inc.. AZ-004 is being developed for the rapid treatment of agitation in schizophrenia or bipolar disorder patients.

20 Oct 2010

Researchers to study effectiveness of gamma-tocotrienol on prostate cancer cells

Survival rates of the world's most common cancer might soon be increased with a new vitamin E treatment which could significantly reduce tumour regrowth. Queensland University of Technology (QUT) prostate cancer researchers are leading the fight against a disease which kills 3000 Australian men a year.

20 Oct 2010

Ceregene commences enrollment in CERE-120 Phase 2b study for Parkinson's disease

Ceregene, Inc., a biopharmaceutical company, announced today that enrollment has begun in a new double-blind sham surgery-controlled Phase 2b study evaluating CERE-120 in Parkinson's disease patients. CERE-120 is a gene therapy product that delivers the neurotrophic factor neurturin to degenerating or dying dopamine neurons. Data from the first Phase 2 clinical trial of CERE-120 are being published later this year in Lancet Neurology (to appear online October 21, 2010).

20 Oct 2010

Boeing to shift health costs to workers

The Wall Street Journal: Boeing will increase the costs of health insurance for its 90,000 nonunion workers next year in response to rising health costs, spurred, in part, a Boeing official said, by the federal health law. The company plans to "phase in higher employee costs for deductibles, co-payments and co-insurance during 2011.

20 Oct 2010

ThermoGenesis enters licensing agreement with BioParadox for Res-Q technology

ThermoGenesis Corp. a leading supplier of innovative products and services that process and store adult stem cells, said today it has entered into a license and distribution agreement for its Res-Q 60 BMC (Res-Q) System with BioParadox, Inc., a newly-formed regenerative medicine company focusing on point-of-care cardiovascular therapies.

20 Oct 2010

Anticoagulant Pradaxa receives FDA approval for prevention of stroke in atrial fibrillation patients

The U.S. Food and Drug Administration today approved Pradaxa capsules (dabigatran etexilate) for the prevention of stroke and blood clots in patients with abnormal heart rhythm (atrial fibrillation).

20 Oct 2010

Study finds adipose dysfunction linked to steatosis, necroinflammation in G1 CHC patients

Researchers at the University of Palermo in Italy provide the evidence that a higher visceral adiposity index score-a new index of adipose dysfunction-has a direct correlation with viral load and is independently associated with both steatosis and necroinflammatory activity in patients with genotype 1 chronic hepatitis C (G1 CHC).

20 Oct 2010

Autistic children with poor diet face risk of vision loss due to vitamin B12 deficiency

Autistic children with severely limited diets may be at risk for vision loss due to vitamin B12 deficiency, according to new research from The Children's Hospital of Philadelphia. Doctors should consider this deficiency when evaluating and treating children with autism and vision loss, the authors said.

20 Oct 2010

Medical News

Spectral commences pivotal Toraymyxin trial for severe sepsis

ASBP reviews current rules of prescription medication to treat obesity in Kansas

New research blames billions in medical costs on obesity

European Commission grants orphan drug status to OBI-1 for hemophilia treatment

Candidates continue to clash over health care law

En Ze Jia Shi Pharmaceuticals receives patent for controlled-release oral gliclazide

Gilead Sciences third quarter total revenues increase 8% to $1.94 billion

As state commissioners meet on medical loss ratio, insurers warn of impact

Long term exposure to air pollution increases risk of severe COPD

454 Life Sciences enters co-promotional agreement with Fluidigm

State Roundup: Md.'s heath info exchange; LA to cut retiree health benefits; N.Y.'s mental health building boom

CIED implantation with AIGISRx Antibacterial Envelope reduces overall infection rate

Alexza reacquires U.S. and Canadian rights for Staccato Loxapine from BLS

Researchers to study effectiveness of gamma-tocotrienol on prostate cancer cells

Ceregene commences enrollment in CERE-120 Phase 2b study for Parkinson's disease

Boeing to shift health costs to workers

ThermoGenesis enters licensing agreement with BioParadox for Res-Q technology

Anticoagulant Pradaxa receives FDA approval for prevention of stroke in atrial fibrillation patients

Study finds adipose dysfunction linked to steatosis, necroinflammation in G1 CHC patients

Autistic children with poor diet face risk of vision loss due to vitamin B12 deficiency

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News